Skip to main content

Table 8 Base case and sensitivity analysis results

From: Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison

OLAI versus RLAI Incremental (discounted) ICER (discounted)
Cost mean (SD) LYs mean (SD) QALYs mean (SD) Relapses mean (SD) Cost/QALY Cost/relapse avoided Cost/life year gained
Base case -€2939.66 (300.83) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Revised OLAI dosing schedule (2 weekly starting dose & 4 weekly maintenance dose) -€2810.58 (281.38) 0.04 0.021) 0.07 (0.018) −0.41 (0.046) Dominant Dominant Dominant
Discount Rate set to 0% -€3068.23 (321.06) 0.04 (0.027) 0.08 (0.020) −0.42 (0.049) Dominant Dominant Dominant
Discount rate set to 6% -€981.51 (125.16) 0.0001 (0.000) 0.0005 (0.000) −0.42 (0.049) Dominant Dominant Dominant
Relapse rate of OLAI equal to RLAI (0.176) -€2513.30 (286.30) 0.04 (0.024) 0.05 (0.018) −0.34 (0.044) Dominant Dominant Dominant
Discontinuation of OLAI equal to RLAI (0.445) -€1594.46 (324.59) −0.003 (0.027) −0.003 (0.019) −0.07 (0.050) €472796.00 Dominant €491207.00
Maximum number of switches set to 5 -€2937.57 (314.19) 0.04 (0.023) 0.07 (0.017) −0.42 0.050) Dominant Dominant Dominant
Maximum number of switches set to 10 -€2947.24 (318.27) 0.04 (0.022) 0.07 (0.017) −0.42 (0.052) Dominant Dominant Dominant
Cost of routine management1 increased 30% -€3527.51 (371.13) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of routine management1 decreased 30% -€2351.82 (232.74) 0.04(0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Yearly adverse event rate of OLAI equals RLAI -€2878.91 (319.59) 0.04 (0.023) 0.09 (0.016) −0.41 (0.052) Dominant Dominant Dominant
Cost of administration increased 30% -€3083.92 (303.46) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of administration decreased 30% -€2795.41 (298.37) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of administration of OLAI equals RLAI -€3392.17 (301.51) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Time Horizon 1 year -€643.44 (116.98) 0.02 (0.004) 0.02 (0.003) −0.11 (0.023) Dominant Dominant Dominant
Time Horizon 2 years -€1402.48 (168.63) 0.02 (0.009) 0.03 (0.007) −0.21 (0.031) Dominant Dominant Dominant
Time Horizon 3 years -€2005.29 (224.89) 0.02 (0.015) 0.05 (0.011) −0.29 (0.038) Dominant Dominant Dominant
Time Horizon 4 years -€2493.99 (267.06) 0.03 (0.019) 0.06 (0.014) −0.36 (0.044) Dominant Dominant Dominant
Time Horizon 10 years -€4552.43 (513.34) 0.11 (0.057) 0.11 (0.040) −0.72 (0.072) Dominant Dominant Dominant
Time Horizon 15 years -€5491.36 (746.04) 0.19 (0.089) 0.14 (0.059) −0.96 (0.088) Dominant Dominant Dominant
Time Horizon 20 years -€6010.09 (985.99) 0.28 (0.118) 0.16 (0.076 −1.16 (0.111) Dominant Dominant Dominant
Time Horizon 30 years -€6184.28 (1387.21) 0.44 (0.172) 0.20 (0.104) −1.41 (0.144) Dominant Dominant Dominant
Utility tariffs increased 30% -€2939.66 (300.83) 0.04 (0.025) 0.09 (0.024) −0.42 (0.049) Dominant Dominant Dominant
Utility tariffs decreased 30% -€2939.66 (300.83) 0.04 (0.025) 0.05 (0.013) −0.42 (0.049) Dominant Dominant Dominant
Probability of doctors visit for adverse events 5% -€2983.18 (269.74) 0.04 (0.023) 0.07 (0.019) −0.43 (0.044) Dominant Dominant Dominant
Probability of doctors visit for adverse events 15% -€2824.75 (326.69) 0.04 (0.027) 0.07 (0.020) −0.41 (0.050) Dominant Dominant Dominant
Probability of switching treatment following doctors visit for adverse events 5% -€2940.17 (303.80) 0.04 (0.024) 0.07 (0.017) −0.42 (0.051) Dominant Dominant Dominant
Probability of switching treatment following doctors visit for adverse events 25% -€2849.86 (334.18) 0.04 (0.024) 0.07 (0.018) −0.41 (0.054) Dominant Dominant Dominant
Cost of OLAI increased 25% -€152.19 (302.58) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of OLAI decreased 25% -€5727.14 (304.63) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Branded drug costs decreased 7.5% -€2899.05 (296.94) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of concomitant medication increased 25% -€2934.53 (302.95) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of concomitant medication decreased 25% -€2944.80 (298.74) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
  1. 1Including the variables cost of schizophrenia management, inpatient cost of relapse management, outpatient cost of relapse management.
  2. SD = Standard deviation.